Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alto Neuroscience (ANRO) Total Current Liabilities (2023 - 2026)

Alto Neuroscience has reported Total Current Liabilities over the past 4 years, most recently at $13.1 million for Q1 2026.

  • Quarterly results put Total Current Liabilities at $13.1 million for Q1 2026, up 80.72% from a year ago — trailing twelve months through Mar 2026 was $13.1 million (up 80.72% YoY), and the annual figure for FY2025 was $11.3 million, up 13.16%.
  • Total Current Liabilities reached $13.1 million in Q1 2026 per ANRO's latest filing, up from $11.3 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $14.0 million in Q3 2024 and bottomed at $5.6 million in Q4 2023.
  • Median Total Current Liabilities over the past 4 years was $9.4 million (2024), compared with a mean of $9.6 million.
  • The largest annual shift saw Total Current Liabilities plummeted 35.46% in 2025 before it skyrocketed 80.72% in 2026.
  • Over 4 years, Total Current Liabilities stood at $5.6 million in 2023, then surged by 78.4% to $10.0 million in 2024, then increased by 13.16% to $11.3 million in 2025, then grew by 15.81% to $13.1 million in 2026.
  • Business Quant data shows Total Current Liabilities for ANRO at $13.1 million in Q1 2026, $11.3 million in Q4 2025, and $9.0 million in Q3 2025.